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 Increasing numbers of diverse urinary 
biomarkers that facilitate the early, sensi-
tive, and specifi c diagnosis of acute kidney 
injury (AKI) in preclinical and clinical 
studies have been discovered. Th e best-
performing biomarkers allow the diagno-
sis of AKI within a few hours after an 
insult, at a time when renal excretory 
function may still be at baseline, and 
24 – 48  h before serum creatinine levels 
rise. 1 Th e Acute Kidney Injury Network 
(AKIN) diagnostic scoring system is based 
on such a rise of serum creatinine at 48 
hours aft er injury, and a defi ned decrease 
in urine output, variables that may be sub-
ject to confounding factors. 2,3 In analogy 
to the success with early interventions in 
patients with myocardial infarction, in 
whom an early diagnosis is facilitated by 
the use of a sensitive injury marker such 
as troponin, the obvious therapeutic goal 
of an early diagnosis and eff ective therapy 
is to reduce the incidence of signifi cant 
AKI, associated morbidity and mortality 
rates, acute treatment costs, and the late 
development of chronic kidney disease 
that can progress to end-stage renal dis-
ease. And, importantly, the availability of 
well-performing biomarkers will facilitate 
more sensitive efficacy testing of new 
clinical interventions. 
 Novel urinary biomarkers for AKI have 
been categorized as infl ammatory, excreted 
tubular proteins and surrogate markers of 
tubular injury ( Figure 1 ). However, their 
characterization has also resulted in the 
discovery of previously unknown tubular 
responses to acute insults, as has been 
demonstrated for kidney injury molecule-
1 (Kim-1), neutrophil gelatinase-associated 
lipocalin (NGAL), interleukin-18, liver-
type fatty acid-binding protein (L-FABP), 
and others. 1 For example, the administra-
tion of NGAL (lipocalin-2) aff ords protec-
tion against experimental AKI, 4 while 
Kim-1, a type 1 transmembrane protein 
that is highly expressed in dediff erentiated 
proximal tubular cells, is a phosphatidyl-
serine receptor that confers a phagocytic 
phenotype on epithelial cells. Th is allows it 
to recognize apoptosis cell surface-specifi c 
epitopes and thereby enables injured 
 tubular cells to contribute to the clearance 
of apoptotic cells aft er AKI. 5 
 Rouse and colleagues 6 (this issue) con-
ducted studies in rats with gentamicin-
induced AKI, using a dose escalation 
protocol. Changes in the profi les of eight 
commercially available urinary biomark-
ers were tested for their utility in the early 
diagnosis of AKI but, importantly, also 
during spontaneous recovery from AKI. 
Four of these, osteopontin, clusterin, and 
  - and   -glutathione  S -transferases, are 
thought to possess intrinsically expressed 
organ-protective activities. The other 
biomarkers were albumin, Kim-1, lipoca-
lin-2, and renal papillary antigen-1. Ani-
mals were followed for 42 days, renal 
function was monitored, urinary biomar-
kers were assayed with the Meso Scale 
Discovery platform, and observed biomar-
ker changes were compared with parallel 
alterations in kidney mRNA expression of 
 Kim-1 ,  Lipocalin-2 ,  Clusterin , and  Spp1 
(osteopontin); this was complemented by 
blinded histopathology evaluations of the 
kidneys. Th is rigorous and broad-based 
approach to the performance testing of a 
group of biomarkers makes this study par-
ticularly informative. It provides the opti-
mal design according to which the utility 
of clinically used biomarkers should be 
validated, which, as of this date, has not 
been done. Specifi cally, these data demon-
strate compellingly that functional 
changes (loss and recovery, assessed con-
ventionally); survival, if applicable; diag-
nostic alterations in urinary biomarker 
profi les; and corresponding renal expres-
sion levels must be correlated with his-
topathological patterns. In this fashion, 
reliable, specifi c, and sensitive relation-
ships between novel biomarker responses 
to renal injury, their early and specifi c 
diagnostic validity, and their prognostic 
performance (need for renal replacement 
therapy, likelihood of recovery) must be 
established in order to fully confi rm their 
clinical utility. Demonstration of this 
approach is the merit of Rouse and 
colleagues ’ detailed preclinical studies. 6 
 Except for non-diagnostic urinary albu-
min levels, the changes of the other seven 
biomarkers in this paper had a similar time 
course (peaked by about day 7 aft er initia-
tion of gentamicin), exhibited gentamicin 
dose responsiveness, correlated with his-
topathology scores, and were reversible 
with organ repair and recovery of function. 
Although all urinary biomarker results 
were normalized to urinary creatinine, 
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 Novel urinary biomarkers for the early, sensitive, and specific diagnosis 
of acute kidney injury (AKI) show promise for the improved 
management of patients with this treatment-resistant complication. 
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corresponding raw data are also presented, 
and these generally paralleled the normal-
ized data. Interestingly, the performance 
of these kidney injury markers was con-
sistently better during injury than during 
recovery, illustrating diff erent individual 
responsiveness to injury and engagement 
in repair, respectively. Kim-1 exhibited the 
earliest and largest response to gentamicin-
induced AKI and also correlated well with 
evolving histopathological changes. Dur-
ing recovery, Kim-1 and osteopontin best 
refl ected tubular regeneration. Receiver 
operating characteristic curves for all var-
iables were designed from longitudinal 
urinary biomarker data. Rises in blood 
urea nitrogen and serum creatinine were 
detectable only in the high-dose gen-
tamicin group but generally paralleled the 
time course of urinary biomarkers. All uri-
nary biomarkers performed as well as 
blood urea nitrogen, and blood urea nitro-
gen, Kim-1, osteopontin, clusterin, and 
renal papillary antigen-1 outperformed 
serum creatinine. Th e diagnostic  ‘ weak-
ness ’ of changes in serum creatinine in the 
setting of this toxic form of AKI appears to 
parallel its suboptimal performance in 
clinical AKI. Th ese observations warrant 
that a similar systematic investigation in 
ischemia / reperfusion models of AKI, the 
most common form of severe clinical AKI, 
should be conducted next. Because of 
differences in the time course and the 
involved patho- and repair mechanisms, 
urinary biomarker profiles during the 
respective injury and repair phases of 
ischemia / reperfusion injury might be dis-
tinct from patterns observed in this neph-
rotoxic model of AKI. Th is information 
will be of obvious clinical value, and initial 
preclinical and clinical studies have begun 
to examine such injury-specifi c biomarker 
response patterns. 
 A better understanding of the mecha-
nisms whereby certain injury-induced 
biomarkers function in AKI should lead, 
one would expect, to the development of 
novel approaches for the treatment of 
AKI. Such a self-protective role following 
AKI has also been suggested for the 
hematopoietic chemokine and survival 
factor CXCL12 (SDF-1  ), since its renal 
expression is robustly upregulated aft er 
AKI, paralleled by upregulated expression 
of its receptors on renal tubular cells. 7 
 A PubMed search on the renoprotective 
effi  cacy of mechanistically very diverse 
interventions in experimental AKI found 
more than 500 publications since 1966. 
Remarkably, with the exception of a few 
studies, all interventions were tested in 
otherwise healthy animals and not in ani-
mals with those comorbidities (chronic 
kidney disease, the metabolic syndrome, 
older age, diabetes mellitus, proteinuria, 
and so on) that put patients at particularly 
high risk for AKI. 8 And the few bioactive 
factors (IGF-1, ANP, erythropoietin) that 
were clinically tested failed to improve 
outcomes in patients with AKI. 9 – 11 Pos-
sible explanations for these disappointing 
outcomes include the likelihood that 
interventions may have been given when 
the renal insult had become treatment 
resistant and not at comparable times aft er 
injury. Treated cohorts may have been too 
heterogeneous regarding risk factor pro-
fi les and types of renal insult. And, retro-
spectively, the effi  cacy of these factors was 
not pretested in animal models with rel-
evant underlying comorbidities. Another 
reason that may principally contribute to 
the observed treatment resistance of AKI 
patients to these factors may be their lim-
ited ability to adequately and successively 
target all major patho- and repair mecha-
nisms of AKI, such as hemodynamic and 
vascular alterations, infl ammation, oxida-
tive stress, cellular apoptosis and necrosis, 
mitogenesis, and others. Preclinical studies 
from several laboratories and our own have 
shown that mesenchymal stem cell (MSC)-
based inter ventions are able to eff ectively 
target all major components of the com-
plex pathophysiology and repair of AKI, 
mediated primarily through paracrine 
antiapoptotic, anti-inflammatory, 
mitogenic, angiogenic, and other mecha-
nisms. 12 Collectively, these observations 
served as the scientifi c justifi cation for our 
recently completed phase I trial in which 
allogeneic MSCs were administered to 
patients at high risk for AKI after on-
pump cardiac surgery (underlying chronic 
kidney disease, age   >  65 years, diabetes 
mellitus, congestive heart failure). Th e 
administration of allogeneic MSCs was 
safe, and assessment of preliminary effi  -
cacy in this small group of subjects sug-
gested early and late reno protective 
effi  cacy. And urinary levels of interleukin-
18, lipocalin-2, and SDF-1  did not sug-
gest the development of AKI in the 
MSC-treated subjects. 12  
 Taken together, both the negative data 
from the trials described above and the lim-
i ted ability of renal replacement therapy to 
reduce AKI-associated mortality continue 
to underscore the urgent need for funda-
mentally new diagnostic and therapeutic 
approaches in the management of AKI. 
Endre  et al. recently took a biomarker-based 
approach in a very elegantly designed 
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 Figure 1  |  Diversity of urinary biomarkers for AKI. NGAL, neutrophil gelatinase-associated 
lipocalin; SDF-1, stromal cell – derived factor 1. 
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clinical trial, 11 in which   -glutamyl-
transpeptidase and alkaline phosphatase 
served as biomarkers. Patients were enrolled 
on the basis of the diagnostic elevation of 
the calculated product of these biomarkers, 
which were normalized to urinary creati-
nine. Th e fi rst dose of erythropoietin (EPO) 
was given within about 6 hours of the 
biomarker-confi rmed insult, and the sec-
ond dose at 30 hours. Controls with iden-
tical biomarker profi les were treated with 
vehicle. Th e rationale for the use of EPO 
included its demonstrated antiapoptotic, 
anti-infl ammatory, and mitogenic actions 
in EPO receptor-expressing animal and 
renal cells. 13 Disappointingly, EPO failed 
to improve outcomes versus control sub-
jects, indicating that either the biomarkers 
used or the tested treatment protocol may 
have been suboptimal. Th is is again in 
contrast to preclinical studies with EPO, 
all of which showed good renoprotective 
activity in otherwise healthy animals. 
 In conclusion, the current status of opti-
mal biomarker and AKI therapy develop-
ments, as also illustrated by Rouse  et al. , 6 
does identify a number of important 
points: (1) Novel AKI biomarkers, parti-
cularly when used in combination panels, 
possess greater specifi city and earlier diag-
nostic and prognostic sensitivity than 
serum creatinine and blood urea nitrogen, 
during both the injury and the recovery 
phases of AKI. (2) Changes in urinary 
profi les of these very diverse biomarkers 
do largely occur in a temporally parallel 
pattern during the injury (higher specifi -
city) and recovery (lower specificity) 
phases of nephrotoxin-induced AKI. (3) 
Changes in urinary biomarkers illustrate 
distinct renal responses to injury, such 
as shedding of proximal tubular brush bor-
der components and cytosolic proteins /
 enzymes, while also identifying their 
individual roles in defensive and repair-
supporting mechanisms that may serve as 
the basis for the future development of 
novel therapeutic approaches. (4) Initial 
proof of principle for both biomarkers 
(specifi city, sensitivity) and interventions 
(effi  cacy) is most optimally tested in suit-
able clinical AKI models, such as open 
heart surgery patients and kidney trans-
plant recipients. (5) Effi  cacy of novel ther-
apies should be established in relevant 
preclinical animal models. (6) Eff ective 
therapies should optimally target all major 
components of renal injury and recovery. 
(7) It is hoped that select biomarkers may 
aid the physician in pinpointing the time 
when specifi c therapies are most eff ective. 
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cell transplantation. Th e results suggest 
a therapeutic benefit of this approach, 
independent of diff erentiation of the graft  
into a renal cell type, but dependent 
on the level of bone marrow chimerism. 
Chimerism levels correlate with improved 
functional parameters as well as histo-
pathological findings resulting in a 
therapeutic benefi t that cannot easily be 
explained by target tissue diff erentiation 
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 Yeagy and colleagues present long-term data from a preclinical 
model of cystinosis after hematopoietic stem cell transplantation. 
The results suggest a therapeutic benefit independent of target tissue 
differentiation but dependent on the level of bone marrow chimerism. 
The mode of action remains mysterious, but positive effects are seen. 
Although the work presents a potential therapeutic option for an 
otherwise dismal disease, the search for the mechanism of action in 
cellular therapies continues. 
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 Yeagy and colleagues 1 present long term 
follow-up data in a preclinical model of 
cystinosis aft er wild-type or green fl uores-
cent protein-labeled hematopoetic stem 
